Volume 3, Issue 4 (November 2024)
Health Science Monitor 2024, 3(4): 306-323 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Rezaei E, Aliasgarzadeh S, Mikaeili mirak S, Tayyar-Iravanlou F. Factors influencing COVID-19 vaccine breakthrough infections: an analysis of healthcare workers in Ardabil, Iran. Health Science Monitor 2024; 3 (4) :306-323
URL: http://hsm.umsu.ac.ir/article-1-186-en.html
URL: http://hsm.umsu.ac.ir/article-1-186-en.html
Students Research Committee, School of Paramedical Sciences, Ardabil University of Medical Sciences, Ardabil, Iran
Abstract: (707 Views)
Background & Aims: Investigating re-infection with COVID-19 is necessary due to the existence of genetic differences among populations after a general vaccination plan. In addition to genetic differences, gender, age, the presence of underlying diseases, and the type of vaccine are factors that affect the rate and severity of re-infection after vaccination.
Materials & Methods: Demography, physical activity and nutrition, underlying diseases, the period of involvement with the COVID-19 pandemic, and the percentage of re-infection before and after each stage of vaccination of the medical staff at Imam Khomeini Hospital in Ardabil (Iran) were evaluated. Our study was performed in a descriptive-analytical manner among 149 healthcare workers. The data were collected using a valid and reliable questionnaire and analyzed using SPSS version 26.
Results: According to the results, 69.1% of healthcare workers had a positive PCR test or symptoms of COVID-19 before the first injection of the vaccine. The types of injected vaccines included AstraZeneca, Sinopharm, Sputnik V, Bharat, Barekat, Spicogen, and PastoCovac. After the injection of the first dose of the vaccine, the number of severe cases decreased from 30.9% to 10.7%, which indicates the effectiveness of the vaccination.
Conclusion: The lowest rate of re-infection was observed in people with good physical activity compared to those who were less active (9.6% versus 59.6%). The highest rate of re-infection with COVID-19 between the first and second doses of the vaccine was related to Sinopharm, Sputnik V, and AstraZeneca. The highest rate of re-infection (82.7%) was in the age group under 40 years old.
Materials & Methods: Demography, physical activity and nutrition, underlying diseases, the period of involvement with the COVID-19 pandemic, and the percentage of re-infection before and after each stage of vaccination of the medical staff at Imam Khomeini Hospital in Ardabil (Iran) were evaluated. Our study was performed in a descriptive-analytical manner among 149 healthcare workers. The data were collected using a valid and reliable questionnaire and analyzed using SPSS version 26.
Results: According to the results, 69.1% of healthcare workers had a positive PCR test or symptoms of COVID-19 before the first injection of the vaccine. The types of injected vaccines included AstraZeneca, Sinopharm, Sputnik V, Bharat, Barekat, Spicogen, and PastoCovac. After the injection of the first dose of the vaccine, the number of severe cases decreased from 30.9% to 10.7%, which indicates the effectiveness of the vaccination.
Conclusion: The lowest rate of re-infection was observed in people with good physical activity compared to those who were less active (9.6% versus 59.6%). The highest rate of re-infection with COVID-19 between the first and second doses of the vaccine was related to Sinopharm, Sputnik V, and AstraZeneca. The highest rate of re-infection (82.7%) was in the age group under 40 years old.
Type of Study: Research |
Subject:
Health Protection including control of communicable and non-communicable diseases
Received: 2024/07/2 | Accepted: 2024/09/17 | Published: 2024/11/20
Received: 2024/07/2 | Accepted: 2024/09/17 | Published: 2024/11/20
References
1. Alemayehu A, Demissie A, Yusuf M, Abdullahi Y, Abdulwehab R, Oljira L, et al. COVID-19 vaccine side effect: age and gender disparity in adverse effects following the first dose of AstraZeneca COVID-19 vaccine among the vaccinated population in Eastern Ethiopia: a community-based study. SAGE Open Medicine. 2022 Jul 6;10:20503121221108616.
https://doi.org/10.1177/20503121221108616 [DOI] [PMID] [PMCID]
2. Alishaq M, Nafady-Hego H, Jeremijenko A, Al Ajmi JA, Elgendy M, Vinoy S, et al. Risk factors for breakthrough SARS-CoV-2 infection in vaccinated healthcare workers. PLoS One. 2021 Oct 15; 16 (10):e0258820.
https://doi.org/10.1371/journal.pone.0258820 [DOI] [PMID] [PMCID]
3. Amanat F, Krammer F. SARS-CoV-2 Vaccines: Status Report. Immunity. 2020 Apr 14;52(4):583-589.
https://doi.org/10.1016/j.immuni.2020.03.007 [DOI] [PMID] [PMCID]
4. Zhu FC, Li YH, Guan XH, Hou LH, Wang WJ, Li JX, et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. The Lancet. 2020 Jun 13;395(10240):1845-54. [DOI] [PMID]
5. Babamahmoodi F, Saeedi M, Alizadeh-Navaei R, Hedayatizadeh-Omran A, Mousavi SA, Ovaise G, et al. Side effects and Immunogenicity following administration of the Sputnik V COVID-19 vaccine in health care workers in Iran. Scientific Reports. 2021 Nov 2;11(1):21464.
https://doi.org/10.1038/s41598-021-00963-7 [DOI] [PMID] [PMCID]
6. Kale P, Gupta E, Bihari C, Patel N, Rooge S, Pandey A, et al. Clinicogenomic analysis of breakthrough infections by SARS CoV2 variants after ChAdOx1 nCoV-19 vaccination in healthcare workers. medRxiv. 2021 Jul 3:2021-06.
https://doi.org/10.1101/2021.06.28.21259546 [DOI]
7. Ben Fredj S, Ghammem R, Zammit N, Maatouk A, Haddad N, Haddad N, et al. Risk factors for severe Covid-19 breakthrough infections: an observational longitudinal study. BMC Infectious Diseases. 2022 Nov 28;22(1):894. [DOI] [PMID] [PMCID]
8. Kaur U, Bala S, Ojha B, Jaiswal S, Kansal S, Chakrabarti SS. Occurrence of COVID‐19 in priority groups receiving ChAdOx1 nCoV‐19 coronavirus vaccine (recombinant): A preliminary analysis from north India. Journal of Medical Virology. 2022 Jan [DOI]
10. Bergwerk M, Gonen T, Lustig Y, Amit S, Lipsitch M, Cohen C, et al. Covid-19 Breakthrough Infections in Vaccinated Health Care Workers. New England Journal of Medicine. 2021 Oct 14;385(16):1474-1484.
https://doi.org/10.1056/NEJMoa2109072 [DOI] [PMID] [PMCID]
11. Tyagi K, Ghosh A, Nair D, Dutta K, Singh Bhandari P, Ahmed Ansari I, et al. Breakthrough COVID19 infections after vaccinations in healthcare and other workers in a chronic care medical facility in New Delhi, India. Diabetes and Metabolic Syndrome: Clinical Research and Reviews. 2021 May-Jun;15(3):1007-1008.
https://doi.org/10.1016/j.dsx.2021.05.001 [DOI] [PMID] [PMCID]
12. Blenkinsopp A, Duerden M, Blenkinsopp J. Symptoms in the pharmacy: a guide to the management of common illnesses. John Wiley & Sons; 2022 Oct 10. [Google Books]
13. Klugar M, Riad A, Mekhemar M, Conrad J, Buchbender M, Howaldt HP, Attia S. Side Effects of mRNA-Based and Viral Vector-Based COVID-19 Vaccines among German Healthcare Workers. Biology. 2021 Aug 5;10(8):752.
https://doi.org/10.3390/biology10080752 [DOI] [PMID] [PMCID]
14. Ku EJ, Song K, Kim KM, Seo GH, Yoo SJ. Mortality and Severity of Coronavirus Disease 2019 in Patients with Long-Term Glucocorticoid Therapy: A Korean Nationwide Cohort Study. Endocrinology and Metabolism. 2023 Apr;38(2):253-259.
https://doi.org/10.3803/EnM.2022.1607 [DOI] [PMID] [PMCID]
15. Johnson S, Mielke N, Mathew T, Maine GN, Chen NW, Bahl A. Predictors of hospitalization and severe disease due to breakthrough SARS-CoV-2 infection in fully vaccinated individuals. Journal of the American College of Emergency Physicians Open. 2022 Jul 29;3(4):e12793.
https://doi.org/10.1002/emp2.12793 [DOI] [PMID] [PMCID]
16. Enayatrad M, Mahdavi S, Aliyari R, Sahab-Negah S, Nili S, Fereidouni M, et al. Reactogenicity within the first week after Sinopharm, Sputnik V, AZD1222, and COVIran Barekat vaccines: findings from the Iranian active vaccine surveillance system. BMC Infectious Diseases. 2023 Mar 10;23(1):150. [DOI] [PMID] [PMCID]
17. Lim SY, Jung J, Kim JY, Park S, Kwon JS, Park SY, et al. Breakthrough infections and waning immune responses with ChAdOx1 nCoV-19 or mRNA vaccine in healthcare workers. Clinical and Translational Medicine. 2022 Apr;12(4). [DOI] [PMID] [PMCID]
18. Teran RA, Walblay KA, Shane EL, Xydis SH, Gretsch S, Gagner A, et al. Postvaccination SARS-CoV-2 Infections Among Skilled Nursing Facility Residents and Staff Members - Chicago, Illinois, December 2020-March 2021. Morbidity and Mortality Weekly Report. 2021;70:632-8. http://dx.doi.org/10.15585/mmwr.mm7017e1 [DOI] [PMID] [PMCID]
19. Butt AA, Nafady-Hego H, Chemaitelly H, Abou-Samra AB, Khal AA, Coyle PV, et al. Outcomes among patients with breakthrough SARS-CoV-2 infection after vaccination. International Journal of Infectious Diseases. 2021 Sep;110:353-358.
https://doi.org/10.1016/j.ijid.2021.08.008 [DOI] [PMID] [PMCID]
20. Gohil SK, Olenslager K, Quan KA, Dastur CK, Afsar N, Chang W, et al. Asymptomatic and Symptomatic COVID-19 Infections Among Health Care Personnel Before and After Vaccination. JAMA Network Open. 2021 Jul 1;1(1):e2115980.
https://doi.org/10.1001/jamanetworkopen.2021.15980 [DOI] [PMID] [PMCID]
21. Lee CJ, Woo W, Kim AY, Yon DK, Lee SW, Koyanagi A, et al. Clinical manifestations of COVID-19 breakthrough infections: A systematic review and meta-analysis. Journal of Medical Virology. 2022 Sep;94(9):4234-4245.
https://doi.org/10.1002/jmv.27871 [DOI] [PMID] [PMCID]
22. Lim SY, Jung J, Kim JY, Park S, Kwon JS, Park SY, et al. Breakthrough infections and waning immune responses with ChAdOx1 nCoV-19 or mRNA vaccine in healthcare workers. Clinical and Translational Medicine. 2022 Apr;12(4):e804.
https://doi.org/10.1002/ctm2.804 [DOI] [PMID] [PMCID]
23. COVID-19 Vaccine Breakthrough Case Investigations Team. COVID-19 Vaccine Breakthrough Infections Reported to CDC - United States, January 1-April 30, 2021. Morbidity and Mortality Weekly Report. 2021 May 28;70(21):792-793.
https://doi.org/10.15585/mmwr.mm7021e3 [DOI] [PMID] [PMCID]
24. Islam MZ, Riaz BK, Akbar Ashrafi SA, Farjana S, Efa SS, Khan MA. Severity of COVID-19 reinfection and associated risk factors: findings of a cross-sectional study in Bangladesh. medRxiv. 2022. Https://doi.org/10.1101/2021.12.26.21268408. [DOI]
25. Besharat S, Alamda NM, Dadashzadeh N, Talaie R, Mousavi SS, Barzegar A, et al. Clinical and Demographic Characteristics of Patients with COVID-19 Who Died in Modarres Hospital. Open Access Macedonian Journal of Medical Sciences. 2020 Sep. 20 (cited 2023 Apr. 4);8(T1):144-9. Available from: https://oamjms.eu/index.php/mjms/article/view/5013 [DOI]
26. Nabilou B, Hamdollahzadeh A, Yusefzadeh H. The performance of a cardiovascular hospital in COVID-19 pandemic: a case study of a Middle East developing country. Health Science Monitor 2024; 3 (3) :261-268.URL: http://hsm.umsu.ac.ir/article-1-170-en.html [DOI]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
